Blog

Vivek Subbiah: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6.

Photo taken from Vivek Subbiah/Twitter

Oct 5, 2023, 17:41

Vivek Subbiah: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6.

Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on X/Twitter:

“ANNOUNCEMENT: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6. Super thrilled to co-Chair a very important session on Tumor Agnostic and Precision Medicine with Dr. Francesco Pignatti, Head of Oncology, Haematology, Diagnostics – Safety and Efficacy Sector at European Medicines Agency (EMA).
What are the current roadblocks to histology agnostic biomarker driven approvals?
Hear directly from speakers from US FDA, EMA and from the patient perspective.”

For more information click here.
Source: Vivek Subbiah/Twitter.

Announcement cancer Diagnostics EMA ESMO European Medicines Agency Francesco Pignatti Hematology OncoDaily Oncology patient Precision Medicine US FDA Vivek Subbiah

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success